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Interactions with receptors for the Fc region of IgG (FcγRs) have been shown to 
contribute to the in  vivo protection against influenza A viruses provided by broadly 
neutralizing antibodies (bnAbs) that bind to the viral hemagglutinin (HA) stem. In partic-
ular, Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) has been shown to 
contribute to protection by stem-binding bnAbs. Fc-mediated effector functions appear 
not to contribute to protection provided by strain-specific HA head-binding antibodies. 
We used a panel of anti-stem and anti-head influenza A and B monoclonal antibodies 
with identical human IgG1 Fc domains and investigated their ability to mediate ADCC-
associated FcγRIIIa activation. Antibodies which do not interfere with sialic acid binding 
of HA can mediate FcγRIIIa activation. However, the FcγRIIIa activation was inhibited 
when a mutant HA, unable to bind sialic acids, was used. Antibodies which block sialic 
acid receptor interactions of HA interfered with FcγRIIIa activation. The inhibition of 
FcγRIIIa activation by HA head-binding and sialic acid receptor-blocking antibodies was 
confirmed in plasma samples of H5N1 vaccinated human subjects. Together, these 
results suggest that in addition to Fc–FcγR binding, interactions between HA and 
sialic acids on immune cells are required for optimal Fc-mediated effector functions by 
anti-HA antibodies.
Keywords: hemagglutinin, Fc-receptor, stem-binding antibody, head-binding antibody, aDcc, cr9114, cr6261, 
cr8033
inTrODUcTiOn
Influenza viruses cause annual epidemics that affect 5–15% of the global population, resulting in 
approximately 3–5 million cases of severe illness and up to 500,000 deaths worldwide, particularly 
among the very young, the elderly, and the chronically ill (1–3). In addition, virus strains entering 
the human population from animal reservoirs occasionally give rise to pandemics increasing these 
numbers significantly (4).
Vaccination is considered the most effective way to lower influenza-related disease burden. 
Current influenza vaccines mainly aim to elicit antibodies that prevent the virus from interact-
ing with the sialic acids on the host cells by targeting the head domain of hemagglutinin (HA), 
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the major glycoprotein of the virus. However, since the head 
domain of the HA where the receptor-binding site is located 
evolves rapidly, influenza viruses often escape elimination by the 
immune system. Consequently, current influenza vaccines typi-
cally provide protection against narrow spectra of virus strains 
and must be updated regularly to match the circulating stains. 
Clearly, the development of a next generation of vaccines able to 
protect against all seasonal, as well as possible, pandemic strains, 
is a health-care priority.
Despite the diversity of the influenza HA, rare antibodies 
with broad in vitro neutralizing activity against influenza viruses 
[broadly neutralizing antibodies (bnAbs)] have been isolated 
from human memory B cells. In agreement with their in  vitro 
activity, passive transfer of broadly neutralizing anti-influenza 
antibodies has been shown to protect mice and ferrets from lethal 
challenge with antigenically diverse viruses (5–12).
The structural characterization of several of these antibodies 
(5–7, 10–15) has revealed epitopes in the head and stem regions 
of the HA, where functional constraints appear to restrict the 
potential for the virus to mutate. These epitopes are of great inter-
est as vaccine targets, and several strategies are being employed 
to generate vaccines that induce broadly reactive antibodies 
(16–18). To be able to effectively design these types of vaccines, 
it is essential to elucidate the underlying molecular mechanisms 
involved in the cross-protective immunity of these broadly reac-
tive antibodies.
Influenza-specific antibodies can block essential steps in the 
viral life cycle. Depending on their epitope, they can directly 
interfere with the viral life cycle by blocking the binding of HA to 
its sialic acid receptors on the host cell, by preventing the low pH-
induced conformational changes of HA required for membrane 
fusion, by inhibiting the cleavage of the HA0 precursor protein, 
or by inhibiting viral egress (5–7, 11, 13, 19, 20). Antibodies can 
also exert anti-viral effects through other mechanisms, includ-
ing effector functions mediated by the Fc part of the antibody 
molecule, such as complement-dependent cytotoxicity (CDC) 
and antibody-dependent cellular cytotoxicity (ADCC) (21–24). 
Involvement of Fc-effector functions, in particular ADCC, has 
been demonstrated in the protection of mice from H1N1 chal-
lenge by bnAb FI6 (5).
Recent publications have shown that broadly reactive anti-HA 
head and stem antibodies require Fc receptor (FcR) engage-
ment for optimal protection, while protection by strain-specific 
anti-HA head antibodies was independent of FcR interactions 
(25–28). In addition, it was shown that only stem-specific and 
broadly reactive anti-head antibodies, and not strain-specific 
anti-HA head antibodies, were able to engage FcγRs to trigger 
ADCC (25). No molecular mechanism to explain this observa-
tion has been proposed to date.
Here, we investigate the molecular mechanisms behind the 
observation that anti-stem antibodies and not anti-head anti-
bodies are able to mediate robust FcγRIIIa activation. A panel of 
influenza A- and B-specific monoclonal antibodies with identical 
human IgG1 Fc domains, making them particularly suitable to 
compare their ability to mediate FcγRIIIa activation, were used. 
We demonstrate that in particular, anti-head antibodies that spe-
cifically inhibit the interactions between the HA receptor-binding 
site and sialic acids on immune cells fail to induce strong FcγRIIIa 
activation. The addition of such anti-head antibodies that block 
receptor binding can interfere with FcγRIIIa activation in human 
plasma. Based on our data, we propose a model that describes 
that optimal HA antibody-mediated FcγRIIIa activity is depend-
ent on the interaction between HA on host cells and sialic acid 
receptors on immune cells.
resUlTs
hai-Positive antibodies are Unable to 
induce robust Fcγriiia activation
We have previously described broadly reactive antibodies that 
were protective in  vivo against group 1 influenza A viruses 
(CR6261) (12, 13), antigenically diverse influenza B viruses 
(CR8033 and CR8071), and both group 1 and group 2 influenza 
A viruses as well as influenza B viruses (CR9114) (20). CR6261 
binds the stem region of HA and neutralizes the virus by 
preventing the conformational changes of this protein that are 
required for the viral fusion process (12). In contrast, CR8033 
and CR8071 bind non-overlapping epitopes in the head region 
of influenza B HA and neutralize in vitro. While CR8033 disrupts 
virus attachment to sialic acids on the surface of host cells – as 
can be measured by the hemagglutination inhibition (HAI) assay 
(HAI+) – CR8071 inhibits the release of progeny viruses from 
infected cells (19, 20). Interestingly, CR9114 binds to an epitope 
in the stem region of HA that is conserved among all influenza A 
and B viruses but only inhibits the viral fusion process of influ-
enza A viruses and thus only has in  vitro neutralizing activity 
against these viruses (20).
To further explore the molecular mechanism by which these 
broadly reactive antibodies provide protection in vivo, we char-
acterized the antibodies, together with antibody 2D1, previously 
shown to inhibit the interaction between the HA and the sialic 
acids of several different H1N1 strains (29), in terms of their 
ability to induce effector functions as measured by a bio assay 
that measures antigen-specific antibody-dependent FcγRIIIa 
activation (30, 31).
The HAI+ antibodies CR8033 and 2D1 showed virtually no 
FcγRIIIa activation, while CR6261, CR8071, and CR9114 were 
able to induce robust FcγRIIIa activation to HA-transfected target 
cells (Figure 1).
sialic acid interactions are required for 
Optimal Fcγriiia activation
The distinction between FcγRIIIa activation mediated by CR6261, 
CR9114, and CR8071 on one hand and CR8033 and 2D1 on the 
other appears to coincide with the ability to block HA–sialic 
acid interaction. This suggests that HA binding to sialic acid on 
immune cells may play a role in FcγRIIIa activation mediated 
by anti-HA antibodies. To investigate the role of HA–sialic acid 
interactions, a mutation in the HA of A/California/07/09 (L195F) 
and B/Florida/04/06 (L201F) was introduced preventing the HAs 
from interacting with sialic acid (non-SA binding HA) (Figure S1 
in Supplementary Material). The FcγRIIIa activation to non-SA-
binding HA mediated by CR9114 was much lower as compared 
FigUre 1 | hai+ antibodies are unable to induce robust Fcγriiia activation. Left panel indicates approximate epitopes of 2D1 (in red), CR9114, and CR6261 
(in blue) superimposed onto A/California/07/09 HA (H1/California) and approximate epitopes of CR8033 (in red), CR8071 (in purple), and CR9114 (in blue) 
superimposed onto B/Florida/4/2006 HA (B/Florida). Right panel indicates HAI and FcγRIIIa activation of antibodies 2D1, CR8033, CR8071, CR6261, and CR9114. 
HAI titers were measured for A/California/07/09 (2D1 and CR6261) or B/Florida/4/2006 (CR8033, CR8071, and CR9114). FcγRIIIa activation was measured using 
A/California/07/09 (2D1 and CR6261) or B/Florida/4/2006 (CR8033, CR8071, and CR9114) HA-transfected target human lung-derived A549 cells at an antibody 
concentration of 5 μg/ml. The FcγRIIIa activity was normalized against the response obtained with 5 μg/ml of CR9114. All antibodies contain identical human IgG1 
Fc domains, making them particularly suitable to compare their ability to mediate FcγRIIIa activation. HAI and FcγRIIIa activity data are representative examples of 
three independent experiments.
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to the FcγRIIIa activation to the wild-type HA (Figures 2A,B), 
while the antibody binding was comparable between the non-SA 
binding and wild-type HA (Figure S1 in Supplementary Material).
The HAI+ antibodies 2D1 and CR8033 prevent the 
HA-expressing target cells from interacting with sialic acids 
on immune cells and may therefore be able to inhibit FcγRIIIa 
activation mediated by the HAI-negative antibodies CR6261, 
CR9114, and CR8071. In agreement with the dependency of 
potent FcγRIIIa activation on sialic acid interactions, 2D1 and 
CR8033 inhibit in a dose-dependent manner the FcγRIIIa activa-
tion induced by CR9114 binding to pH1N1 (A/California/07/09) 
HA and influenza B (B/Florida/04/06) HA, respectively 
(Figures  2C,D). Likewise, the FcγRIIIa activation mediated by 
CR6261 binding to pH1N1 HA and CR8071 binding to influenza 
B HA was inhibited by 2D1 and CR8033, respectively (Figure S2 
in Supplementary Material). These results are consistent with a 
model in which interactions between HA and sialic acid residues 
on immune cells, in addition to the established antibody–FcγR 
interactions, are required for optimal FcγRIIIa activation by anti-
influenza HA antibodies (Figure 3).
The Presence of hai+ antibodies in 
human Plasma inhibits Fcγriiia activation
Upon exposure to influenza by infection or vaccination, humans 
develop both HAI+ and HAI− antibodies (32). To assess whether 
the HAI+ antibodies inhibit FcγRIIIa activation in humans, we 
determined the HAI against H5N1 (A/Vietnam/1194/2004) and 
pH1N1 and FcγRIIIa activation in plasma from participants of a 
phase I dose-escalation study evaluating an H5N1 virosomal vac-
cine adjuvanted with Matrix-M (EudraCT no. 2008-006940-20). 
From the subjects who were vaccinated two times with a 30-μg 
HA dose of Matrix-M (50 μg/dose) adjuvanted virosomal vac-
cine, plasma samples were collected at day 0 (pre-vaccination), 
day 21 (post-prime), and day 42 (post-boost) for analysis. High 
levels of stem-binding antibodies were detected in these subjects 
after prime immunization. These levels were not boosted after the 
second immunization (Figure S4A in Supplementary Material).
HAI+ antibodies against the vaccine homologous H5N1 strain, 
but not against the heterosubtypic pH1N1 strain, were induced, in 
particular, after the second vaccination (Figures 4A,D). In order 
to evaluate the inhibiting effect of HAI+ antibodies, we assessed 
the H5N1 HA-specific FcγRIIIa activation in plasma samples 
taken before (pre-vaccination) and after one (post-prime) and 
two (post-boost) vaccinations.
To quantify the amount of inhibition of FcγRIIIa activation, 
we used a modified four-parameter logistic curve (Eq.  2) to 
model the observed dose–response curve. Using this model, we 
estimated an inhibition corrected for the FcγRIIIa activation dose 
response and determined the area between the estimated and the 
observed dose–response curves as measure for FcγRIIIa activity 
inhibition (for an illustration, see Figure S3 in Supplementary 
Material).
H5N1 HA-specific FcγRIIIa activation was inhibited, in par-
ticular, in plasma taken after the boost immunization (Figure 4E). 
The inhibition of FcγRIIIa activation strongly correlated 
(Kendall’s tau b = 0.697, p < 0.001) with the HAI titers to H5N1 
FigUre 2 | sialic acid interactions are required for optimal Fcγriiia activation. (a,B) depict FcγRIIIa activation against target cells transfected with a 
wild-type HA (blue) or non-SA binding mutant HA (black) of A/California/07/09 (a) or B/Florida/4/2006 (B). (c,D) depict 2D1 or CR8033 (black curves) inhibiting 
FcγRIIIa activation against HA of A/California/07/09 (c) and B/Florida/04/06 (D), respectively, induced by a fixed concentration (0.25 μg/ml) of CR9114. Background 
was determined by titrating in CR8033 or 2D1 to a non-binding antibody control (red dashed lines). As a control, a non-binding antibody was titrated in to the fixed 
concentrations of CR9114 (blue dashed line). RLU is the abbreviation for relative light units. Data presented are representative examples of at least three 
independent experiments.
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(Figure 4F). In line with our proposed model, pH1N1-specific 
FcγRIIIa activation in the absence of detectable HAI antibodies 
was barely inhibited (Figures 4A–C).
We next assessed pH1N1-specific FcγRIIIa activation in pools 
of individual plasma samples that were complemented with four 
different concentrations of the pH1N1 HAI+ antibody 2D1 or 
a control antibody. The levels of stem-binding antibodies were 
unaffected by the addition of 2D1 (Figure S4B in Supplementary 
Material), while both the HAI titers and the inhibition of 
FcγRIIIa activation increased in a 2D1 dose-dependent manner 
(Figures 4G,H). The levels of inhibition of FcγRIIIa activation 
and HAI titers were unaffected when control antibody was used 
(Figures S4C,D in Supplementary Material). The inhibition of 
FcγRIIIa activation strongly correlated with the HAI response 
against pH1N1 (Kendall’s tau b = 0.795, p < 0.001, Figure 4I), 
thereby confirming our results obtained with the monoclonal 
antibodies.
DiscUssiOn
The identification and structural characterization of human anti-
bodies with broad neutralizing activity against influenza viruses 
has raised hopes for the development of broad-spectrum anti-
body-based therapy and universal vaccines (33–37). Functional 
characterization of such bnAbs has revealed that depending on 
where they bind the HA molecule, they can directly interfere 
with the viral life cycle by blocking the binding of HA to its sialic 
acid receptors on the host cell, by preventing the low pH-induced 
conformational changes of HA required for membrane fusion, 
by inhibiting the cleavage of the HA0 precursor protein, or by 
FigUre 3 | Proposed model of differential effects of anti-stem (in blue), anti-head non-receptor blocking (hai−) (in purple), and anti-head receptor 
blocking (hai+) (in red) ha antibodies on target cell and immune cell interactions, using wild-type and non-sa-binding mutant ha, and the resultant 
effect on Fcγriiia activation.
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inhibiting viral egress (5–7, 11, 13, 19, 20). In addition, effector 
functions mediated by the Fc part of the antibody molecule, such 
as CDC and ADCC (21), are involved in the protection against 
influenza as demonstrated in the protection of mice from H1N1 
challenge by the bnAb FI6 (5).
Here, we use a bioassay to measure FcγRIIIa activation. 
FcγRIIIa is mainly expressed on human natural killer (NK) cells, 
and its activation leads to the release IFN-γ and cytotoxic media-
tors, such as perforin and granzyme that promotes cell death by 
triggering apoptosis (ADCC). The FcγRIIIa activation assay that 
we used correlates well with standard ADCC assays such as the 
classic PBMC-based ADCC assay as was determined by measur-
ing the FcγRIIIa activation of different isotypes or fucosylation 
variants of human anti-CD20 and anti-EGFR antibodies (30, 
38). FcγRIIIa in not exclusively expressed on NK cells but also 
on a subset of macrophages. Therefore, it may be that antibod-
ies that induce FcγRIIIa activity also are able to induce other 
Fc-dependent effector function such as antibody-dependent 
cellular phagocytosis (ADCP).
Here, we show by analysis of a panel of monoclonal antibodies 
and human plasma samples from individuals vaccinated with an 
H5N1 vaccine that, in addition to FcγR interactions, interactions 
between HA on host cells and sialic acids on immune cells are 
required for optimal FcγRIIIa activation by anti-influenza HA 
antibodies.
Our finding could provide an explanation for recent results 
describing that FcγR interactions contribute to the in vivo efficacy 
of HA stem-binding, but not head-binding, antibodies against 
influenza A viruses (25, 26). In agreement with the previous 
observation, we found that the anti-head antibodies CR8033 and 
2D1 did not efficiently induce ADCC in vitro, in contrast to the 
anti-stem antibodies CR6261 and CR9114. However, a robust 
FcγRIIIa activation was induced by another broadly reactive anti-
head antibody, CR8071. The observation that not anti-HA head 
antibodies per se, but anti-HA head antibodies that block binding 
of HA to its sialic acid receptor, reduce FcγRIIIa activation led 
us to hypothesize that interactions between HA and sialic acid 
residues on immune cells, in addition to Fc–FcγR interaction, are 
needed to mediate optimal ADCC by anti-HA antibodies.
Cooperative binding of both cell-surface proteins (such as 
ICAM-1) and viral proteins (HA in the case of influenza) is 
known to play a role in the innate immune response to influenza; 
for example, it has been shown to be essential for NK cells to 
stimulate the formation of granules (39). This interaction between 
NK cells and HA was found to be dependent on sialylation of the 
NK cell receptor NKp46 (40), and NA-mediated removal of sialic 
acids from the NKp46 receptor on NK cells has been shown to 
constitute an immune-evasion mechanism of influenza viruses 
(41). In line with these findings, alterations in influenza viruses 
that lead to reduced affinity for sialic acid are associated with 
lower levels of innate NK cell activity (42).
It has been shown that immune complexes of anti-HA stem 
antibodies and HA are able to efficiently engage activating FcγRs, 
while immune complexes of an FcγR-blocking anti-HA head 
antibody and HA are not (25). However, an Fc point mutation 
that augments interactions with such activating FcγRs (GASD/
ALIE mutant) restored FcγR binding, demonstrating that the Fc 
region of the anti-HA head antibody is accessible to FcγRs and 
not sterically hindered or spatially disrupted (25).
These findings are in line with, and explained by, a model 
in which Fc–FcγR interactions alone are not sufficient to 
efficiently mediate FcγR activation, and additional interactions 
between HA and sialic acids on the surface of immune cells are 
required (Figure 3) to reach high enough avidity between target 
and immune cell to trigger FcγR activation. They also suggest 
that lack of sialic acid binding can partially be overcome by 
mutations that increase the affinity of the antibody’s Fc domain 
for FcγRs.
We confirmed that the interactions between HA and sialic 
acid and between Fc and FcγR are both required for optimal 
FcγRIIIa activation by anti-influenza HA antibodies in poly-
clonal human plasma samples. Although these results endorse 
that FcγR activation is an important mechanism through which 
bnAbs provide protection against heterologous influenza strains, 
it is unclear what the contribution is against vaccine homolo-
gous strains, thus, in the presence of HAI+ antibodies. We have 
shown that HAI+ antibodies inhibit FcγRIIIa activation in 
human plasma and thereby are likely to reduce its contribution 
FigUre 4 | hai titers strongly correlate with inhibition of Fcγriiia activity by human plasma. (a,D) depict HAI responses of individual samples against 
pH1N1 (a) and H5N1 (D). (B,e) depict pH1N1 HA-specific (B) and H5N1-specific (e) FcγRIIIa activation by individual samples. Black lines indicate the group 
median. (g) depicts the HAI response, and (h) depicts the pH1N1-specific FcγRIIIa activation inhibition of human plasma pools complemented with four different 
concentrations of mAb 2D1. Plasma samples taken before vaccination are indicated in gray (pre), 21 days after the prime in red (post-prime), and 21 days after the 
boost in blue (post-boost). The correlations between HAI responses and FcγRIIIa activation inhibition as determined by the Kendall’s tau-b method are depicted in 
(c,F,i). The correlation is considered significant when p < 0.05. ABC indicates area between curves.
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to protection. However, if the levels of HAI+ antibodies are high 
enough, they are able to prevent infection and effectively protect 
the host, independent from FcγRIIIa activation. Further stud-
ies are required to establish the implications for broad reactive 
influenza vaccines.
The fact that HAI+ antibodies inhibit FcγRIIIa activation in 
humans should be considered when accurate measurements of 
FcγRIIIa activation or ADCC activity are required.
Future vaccination strategies should take into account that – 
next to the induction of potent neutralizing antibodies – optimal 
effector functions may be an important hallmark of vaccine 
efficacy.
eXPeriMenTal PrOceDUres
antibody Production
Human IgG1 antibodies, CR6261, CR9114, CR8033, and CR8071, 
were constructed by cloning the heavy (VH) and light (VL) chain 
variable regions into a single expression vector containing either 
the wild-type IgG1 constant regions or an L234A + L235A double 
mutant (for CR8033 LALA) that abolishes the ability of the Fc 
part of the antibody to interact with FcγR. The variable heavy 
and light chain of 2D1 (29) was also cloned into the same human 
IgG expression vector. The resulting IgG1 had identical specific-
ity as the published antibodies (data not shown). The antibodies 
7Cox et al. Role of Sialic Acids in HA-Mediated FcR Activity
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were produced on HEK293-F cells that were transfected with the 
IgG expression constructs, and the expressed antibodies were 
purified from serum-free culture supernatants using protein A 
chromatography (HiTrap, GE Healthcare, Buckinghamshire, 
United Kingdom) followed by a desalting step (HiPrep 26/10, GE 
Healthcare).
human Plasma samples
Sixty healthy volunteers (22 males and 28 females) aged 
20–49 years (mean age 31.2 years) were recruited into this clinical 
trial to evaluate a virosomal H5N1 vaccine that was performed 
between March and June 2009 at Haukeland University Hospital, 
Bergen, Norway. The open label phase I dose-escalating study 
was approved by the Regional Ethics Committee [Regional 
Committee for Medical Research Ethics, Northern Norway 
(REK Nord)] and the Norwegian Medicines Agency and reg-
istered in the European Clinical Trials Database (EudraCT no. 
2008-006940-20). Informed consent was obtained from subjects 
prior to inclusion in the study. The subjects had never received 
an H5-based vaccine. Participants were randomly divided into 
four groups (n = 15) and vaccinated two times with 30-μg HA 
dose of non-adjuvanted vaccine or 1.5-μg HA, 7.5-μg HA, or 
30-μg HA Matrix-M (50 μg/dose) adjuvanted virosomal vaccine, 
respectively, at days 0 and 21. At days 0, 21, 42, and for 6 and 
12 months, blood samples were collected for analysis (43). For the 
current study, plasma samples collected at day 0 (unvaccinated; 
visit 1), 21 (after prime; visit 2), and 42 (after boost; visit 3) for the 
participants who received 30-μg HA adjuvanted with Matrix-M 
were used.
hemagglutination inhibition assay
Influenza virus H1N1 A/California/07/09 reassortant (NYMC 
X-181), B/Florida/04/06 (wild-type), or H5N1 A/Hong 
Kong/156/97 reassortant (four HA units per well) were combined 
in quadruplicate wells with an equal volume of antibody serially 
diluted in PBS. Plates were incubated for 1 h at 37°C in 96-well 
V-bottom plates. Fifty microliters of 1% turkey red blood cells was 
then added to each well and incubated for 1 h at room tempera-
ture. Button formation was scored as evidence of HAI. Titers were 
determined using the Spearman–Kärber formula.
ha-Binding assay
Binding of antibodies to wild-type and mutant influenza A 
and B HAs was tested by transfecting A549 cells with full-
length recombinant HAs using Lipofectamin 2000 (Invitrogen, 
Carlsbad, CA, USA) to produce surface-expressed HA. On 
the following day, the cells were transferred to 96-well plates 
(PDL-coated black clear bottom) at a density of 1.5  ×  104 
cells per well and incubated. Twenty-four hours later, cells 
were fixed (3% PFA, 15  min), washed, and incubated for 1  h 
with PBS/2%BSA at room temperature. Next, independent 
duplicates of serial antibody dilutions starting at 10  μg/ml 
were added to the cells (50  μl/well) and incubated for 3  h 
at room temperature, followed by wash steps and 30-min 
incubation with the secondary antibody [goat-anti-human IgG 
F(c) IRDye® 800CW Conjugated] (Rockland, Limerick, ME, 
USA) diluted 1/500 in 5 PBS/2%BSA. After an additional wash 
step and fixation (1% PFA), fluorescence was measured on an 
Odyssey classic imager (Licor, Lincoln, NE, USA).
cr9114 competition elisa
To determine stem-binding antibody responses, we measured 
CR9114-competing antibody responses as described before 
(44). Briefly, Maxisorp 96-well plates (Merck) were coated with 
purified polyclonal rabbit anti His-Tag IgG (Genscript, NJ, USA) 
O/N at 4°C followed by washing. After blocking and washing, 
plates were incubated with a titrated amount of His-Tagged HA 
of A/California/07/09 (in house produced and purified) for 2 h 
at RT. Plates were washed, and plasma was added to the plate in 
duplicate, serially diluted in block buffer, and incubated for 1 h 
at RT, followed by addition of a titrated amount of biotinylated 
human IgG1 CR9114 (produced and purified in house) and incu-
bation for another hour at RT. After washing, streptavidin–HRP 
was added and incubated for 1  h at RT, followed by washing 
and OPD (Thermo Scientific, Bremen, Germany) development. 
The colorimetric reaction was stopped after 10  min by adding 
1M H2SO4. The optical density (OD) was measured at 492 nm, 
and standard curves were created using a four-parameter logistic 
curve. The CR9114 competition of each sample was quantified 
as the slope of the linear regression of OD value on the log 10 
dilution for the duplicate series.
Fcγriiia activation assay
Human lung carcinoma-derived A549 epithelial cells (ATCC 
CCL-185) were maintained in Dulbecco’s modified eagle medium 
(DMEM, Invitrogen) medium supplemented with 10% heat-
inactivated fetal calf serum at 37°C. The A549 cells were trans-
fected with wild-type B/Florida/04/2006 or A/California/07/09 
(pH1N1) HA expression vectors or corresponding (non-sialic 
acid-binding mutants), using Lipofectamine 2000 (Invitrogen). 
The next day, 1.5 × 104 A549 cells were seeded in white opaque 
flat bottom 96-wells plates. Eighteen hours later, antibodies or 
human plasma samples were serially diluted in assay buffer [4% 
ultra-low IgG FBS (Invitrogen) in RPMI 1640 (Invitrogen)]. 
Sample (antibody or human plasma) dilutions and ADCC 
Bioassay Jurkat effector (immune) cells expressing human 
FcγRIIIa and an NFAT-response element regulating a luciferase 
reporter gene (V158 variant provided by Promega, Fitchburg, 
MA, USA) were added to the cells and incubated for 6  h at 
37°C. Cells were equilibrated at room temperature for 15 min 
before Bright-Glo luciferase substrate (Promega) was added. 
Luminescence was read out after 5 min on a Trilux Microbeta 
plate reader.
The interference experiments with monoclonal antibodies were 
performed in a similar fashion; however, instead of transfecting 
the A549 target cells with HA-expressing vectors, virus infection 
was used to obtain HA-expressing target cells. Therefore, 2 days 
before the experiment, 1.5 × 104 A549 cells were seeded in white 
opaque flat bottom 96-well plates. One day before, the experi-
ment cells were infected with 12,000 TCID50 per well influenza 
virus. The next day, independent duplicates of 2D1 or CR8033 
LALA mutant (because wild-type CR8033 applied in very high 
concentrations did induce some FcγRIIIa activation) were 
eightfold serially diluted in assay buffer (4% ultra-low IgG FBS 
8Cox et al. Role of Sialic Acids in HA-Mediated FcR Activity
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 399
in RPMI 1640), and a fixed concentration of CR6261, CR9114, 
CR8071, or control antibody was added to each dilution. FcγRIIIa 
activity was normalized to the FcγRIIIa activity obtained with 
control antibody.
The interference by different concentrations of 2D1 or control 
antibody (4.1, 52.3, and 209 μg) in pooled plasma samples (an 
equal amount of the individual plasma samples per time point 
were pooled) was performed on A/California/07/09 (pH1N1) 
HA expression target cells as described above.
Quantification of Fcγriiia activity 
interference
FcγRIIIa activity dose–response curves are routinely fitted using 
a four-parameter logistic curve (Eq. 1). Here, the dose–response 
curve is summarized into four parameters: a lower asymptote 
(A), an upper asymptote (D), the inflection point (C), and a slope 
factor (B).
 RLUlog log= + − × + − ×
A D A C X B( ) ( )
1
1 10
 (1)
which is equivalent to fitting a linear effect in logit-log space.
An inhibition of FcγRIIIa activity, reflected by a hook effect 
in the dose–response curve (Figure S4B in Supplementary 
Material, black dots), can be seen as a combination of an active 
and an opposite inhibition dose–response curve (Figure S4B in 
Supplementary Material, respectively, curves 1 and 2). When 
assuming that (i) the non-inhibited maximum FcγRIIIa activation 
(parameter D) and the minimum FcγRIIIa activation (parameter 
A) are shared between the two dose–response curves and that 
the two dose–response curves share a common (but opposite) 
slope factor, the four-parameter logistic curve can be modified to 
model 2 opposite linear effects simultaneously:
 RLUlog log log= + − × +
×
+− × − ×− ×
A D A C X B IC X B( ) ( ) ( )
1
1 10
1
1 10 1
 (2)
where B represents the slope factor for the active dose–response 
curve, C and IC represents the inflection point of the active and 
the inhibiting dose–response curve, respectively (Figure S4B in 
Supplementary Material, curve 3).
For each subject, the amount of inhibition of FcγRIIIa activity 
at day 0 (unvaccinated; pre), at day 21 (post prime), and at 
day 42 (post boost) was determined by using Eq.  2 with time 
point-specific parameter estimates for C, IC, B, and D, whereas 
the estimate for A was shared between all three time points. 
In addition, to accommodate a possible vaccination effect on 
the FcγRIIIa activation (i.e., increase in FcγRIIIa activity at 
post prime or post boost), the model was constrained in such 
a way that the upper asymptote of the dose–response curves 
post prime or post boost had to be equal to, or higher than, the 
upper asymptote at pre-vaccination (i.e., dotted line in Figure 
S4A in Supplementary Material). For the data where antibody 
was spiked in a pool of sera, a similar approach was followed, 
without the constraint for the upper asymptote. The inhibition 
was then quantified as the area between the predicted (inhibition 
corrected) FcγRIIIa activity dose–response curve and observed 
dose–response curve (Figure S4C in Supplementary Material, 
area between, respectively, curves 1 and 3, depicted in green). 
Correlation between HAI titer and the amount of FcγRIIIa 
activity inhibition (i.e., area between curves) was assessed using 
Kendall’s tau-b.
generation of influenza Pseudoparticles
Lentiviral pseudoparticles were generated by co-transfecting 
293T cells using Lipo2000CD (Invitrogen) with pLP1, pLP2, and 
pLenti6-luciferase (Invitrogen), expression plasmids coding for 
influenza HA (wild-type and L201F mutant B/Florida/04/2006), 
neuraminidase (N1 HK/156/1997), and human airway trypsin-
like (HAT, accession number NP_004253.1) (45). One day after 
the transfection, medium was replaced for culture medium 
(DMEM supplemented with l-glutamine, 5-mM MgCl, and 5% 
FBS; Invitrogen), and 96  h after transfection, the supernatants 
were passed through 0.45-μm filters and stored in aliquots at 
−80°C. HA content of pseudoparticles was determined by ELISA 
using anti-HA antibodies as described before (20).
Fetuin elisa
Maxisorp ELISA plates (Merck, Darmstadt, Germany) were 
coated overnight at 4°C with 30 μg/ml Fetuin (Merck) in PBS. 
Plates are blocked with 1% BSA in wash buffer (PBS +  0.05% 
Tween-20). Twofold dilutions of wild-type or L195F mutant 
A/California/07/09 HA or L201F mutant B/Florida/04/06 HA 
pseudotyped particles were added to the wells, and plates were 
incubated for 1.5 h at room temperature. Human CR9114 (2 μg/
ml) and peroxidase-conjugated affinipure mouse anti-human IgG 
(Fcγ fragment specific, 1:1000; Jackson, West Grove, PA, USA) 
were used for detection. Plates were incubated with SigmaFast 
OPD (Merck) for 20 min; reactions were stopped by adding 1M 
H2SO4 and read using a Biotek plate reader.
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